Patient Safety Movement Foundation Announces Winners of 2020 Humanitarian Awards
10.2.2021 16:00:00 EET | Business Wire | Press release
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient deaths by 2030, announced the winners of its 2020 Humanitarian Awards at a virtual ceremony on February 8, 2021. The recipients included Steve Burrows, Vonda Vaden Bates, Marty Hatlie and Barb Pelletreau. Each year the Humanitarian Awards recognize leaders who have made significant progress in the last year eliminating or raising awareness of preventable patient deaths.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005339/en/
Steve Burrows, Vonda Vaden Bates, Marty Hatlie and Barb Pelletreau were recognized by the Patient Safety Movement Foundation for their efforts eliminating and raising awareness of preventable patient deaths (Photo: Business Wire)
“To achieve our goal of zero preventable patient deaths by 2030, it is critical to unify people and collectively improve patient safety across the globe,” said David B. Mayer, MD, CEO of Patient Safety Movement Foundation. “We are pleased to honor each of these individuals for their remarkable efforts to spread public awareness of this important issue and improve the patient experience for everyone.”
The Humanitarian Award recipients were honored across three categories this year – the Judie Burrows award, Michael Seres award and Steven Moreau award. The Judie Burrows award was established to recognize an individual who has told a story of preventable harm or death that has made a significant impact in the public sphere in the last year. The Michael Seres award was designed in honor of lifelong patient safety advocate, Michael Seres, who passed away in May 2020. This award recognizes an individual who contributed to the advancement of person and family engagement, public awareness and public engagement in patient safety. The Steven Moreau award is given to a hospital administrator who possesses a zeal for improving patient safety at their hospital. This year’s recipients included:
- Steve Burrows, writer and director of the acclaimed documentary “Bleed Out,” was recognized with the Judie Burrows award for the impact his HBO film had in elevating the issues around patient safety in the public domain. His documentary follows the story of his mother, Judie Burrows, who experienced a preventable medical error during a partial hip surgery that afflicted her for the rest of her life. Since “Bleed Out” was released in December 2018 over 10 million viewers have watched the film on HBO. Prior to its release, Burrows, his wife Margo and their family thought they were alone, but within the first 24 hours of the film streaming they were inundated with thousands of Facebook messages from strangers who connected with Judie Burrows’ story.
- Vonda Vaden Bates has been passionate about advancing public awareness and engagement around the issue of preventable hospital deaths since losing her husband, Charles “Yogiraj” Bates II, to a preventable venous thromboembolism in 2012. She played an integral role in the conceptualization and success of the #uniteforsafecare campaign – a collaborative effort between the Patient Safety Movement Foundation, American Society of Anesthesiologists (ASA), The Leapfrog Group and International Society for Quality in Health Care (ISQua) to bring attention to system-wide improvements that will ensure better health worker and patient safety outcomes. Bates was recognized with the Michael Seres award for her efforts to advance public awareness and for helping make the #uniteforsafecare campaign and PSMF-hosted events in September 2020 a success.
- Marty Hatlie was also honored with the Michael Seres award. Hatlie has been a lifelong leader in patient safety since he served as executive director of the National Patient Safety Foundation. However, this humanitarian award acknowledges his exemplary work in the last 12 months. Hatlie served as one of the co-chairs for the March for Patient Safety turned #uniteforsafecare campaign. He dedicated much of 2019 and 2020 to launching the initiative.
- Barb Pelletreau, senior vice president of patient safety at CommonSpirit Health (formally known as Dignity Health), received the Steven Moreau award. Pelletreau was recognized for her leadership of the now 150+ hospital system, where she leads patient safety improvement efforts with transparency and candor. Under her leadership, Dignity Health became a PSMF 5-star hospital for making commitments in alignment with the Patient Safety Movement Foundation’s evidence-based Actionable Patient Safety Solutions (APSS) last year, reaffirming its dedication and commitment to zero preventable deaths.
The Patient Safety Movement Foundation launched the Humanitarian Awards in 2013 to recognize individuals whose work helps advance patient safety. To learn more about the awards and past winners, visit: https://patientsafetymovement.org.
To watch the award presentation, visit https://patient.sm/Humanitarian-Awards.
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit on a mission to eliminate preventable deaths from hospital errors. PSMF uniquely brings patients and patient advocates, healthcare providers, medical technology companies, government, employers and private payers together under the same cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org to learn more, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005339/en/
Contact information
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
